Idorsia company profile
Company profile
Idorsia has 424 employees and is headquartered in Allschwil, Switzerland.
QUVIVIQ (daridorexant), a treatment for insomnia, is the product through which many people know Idorsia Ltd, a biopharmaceutical company that discovers, develops and commercializes drugs for unmet medical needs.
Its clinical pipeline covers CNS, cardiovascular, immunological and orphan diseases, with candidates such as lucerastat for Fabry disease, daridorexant for pediatric insomnia, and programs for psoriasis, vitiligo and progressive multiple sclerosis. Collaborations with Janssen Biotech Inc. on aprocitentan and with Viatris Inc. on selatogrel and cenerimod complement a license agreement with Neuro for clazosentan. Its work covers Switzerland, the United States, Japan, Europe, China and Canada.
In the fiscal year ended December 2025, Idorsia reported revenue of CHF 220.6 million, up 96.1% from the previous year, and a net loss of CHF 111.7 million. The company had 424 employees, was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Headquarters
- Hegenheimermattweg 91, 4123, Allschwil
- Employees
- 424
- Chief executive
- Roland Wandeler
- Founded
- 2017
- Fiscal year
- January - December
- Listing
- IDIA · SIX
- Currency
- CHF
- ISIN
- CH0363463438
- Website
- idorsia.com
Idorsia and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| IdorsiaIDIA | Switzerland | $1.26B | 424 | -68.4% | — |
| Pharma MarPHM | Spain | $1.1B | 505 | 21.3% | 14.7 |
| Basilea PharmaceuticaBSLN | Switzerland | $1.07B | 200 | 24.2% | 18.1 |
| PhilogenPHIL | Italy | $905.96M | 230 | 79.1% | 3.67 |
| InventivaIVA | France | $890.8M | 87 | -5,980.9% | — |
| Pharming GroupPHARM | Netherlands | $841.25M | 407 | 12.8% | 36.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
